Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00234910 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients
A Phase 3 study of HIV Infection, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 152
- Enrollment target
- 1
- Study location
NCT00234910: Completed Phase 3 study of HIV Infection, sponsored by Abbott.
NCT00234910 is a Phase 3 study of HIV Infection that has completed, run by Abbott. The registered enrollment target is 152 participants, below the 241-participant average among 73 other HIV Infection trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00234910, a Phase 3 study of HIV Infection, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 152 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to obtain a preliminary assessment of the antiviral activity and tolerability of simplified Kaletra dual agent therapy as initial treatment for HIV infection, relative to a Kaletra three drug standard of care reference arm.
Conditions Studied
Interventions
- DRUG Tenofovir DF
- DRUG lopinavir/ritonavir with 2 Nucleoside RTIs
Study Locations (1)
Illinois
- Global Medical Information-Abbott - Abbott Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
What the finished NCT00234910 record still lists
NCT00234910 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 241-participant average among 73 other HIV Infection trials with a reported enrollment target (37% lower).
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 2 interventions - of which Tenofovir DF is the first listed.
NCT00234910 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00234910 about?
NCT00234910 is a clinical study titled "Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients". The purpose of this study is to obtain a preliminary assessment of the antiviral activity and tolerability of simplified Kaletra dual agent therapy as initial treatment for HIV infection, relative to a Kaletra three drug standard of care reference arm.
What is the current status of trial NCT00234910?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 152 participants. The study started on 2005-01. Estimated completion is 2008-06.
What conditions does trial NCT00234910 study?
This clinical trial studies the following conditions: HIV Infection.
What interventions are being tested in trial NCT00234910?
The interventions under investigation include: Tenofovir DF (DRUG), lopinavir/ritonavir with 2 Nucleoside RTIs (DRUG).
Who is sponsoring clinical trial NCT00234910?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00234910 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00234910's enrollment target sits among peer trials
152 21st of 73 higher than 53 of 73 other HIV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
ACTIVE NOT RECRUITING · Phase 3
-
Comparative Study of Three NNRTI-Sparing HAART Regimens
COMPLETED · Phase 3
-
A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy
COMPLETED · Phase 3
-
B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
COMPLETED · Phase 3
-
Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)
COMPLETED · Phase 3
-
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia